Coverage
-
March 02, 2022
Investors in defunct biotech company TerraVia Holdings Inc. have inked a $2.5 million deal to end claims that the company and its executives concealed reports linking the company's algae ingredients to gastrointestinal distress.
3 other articles on this case.
View all »